Latest news with #BioMarinPharmaceutical
CNBC
3 days ago
- Business
- CNBC
Cramer's Lightning Round: Union Pacific is a buy
BioMarin Pharmaceutical: "I'm getting tired of the orphan drug model...I don't think it works now." Union Pacific: "I think it's a buy...I think it's a really good stock to own." GitLab: "I was prepared for disappointment and I got it...I just do not want enterprise software. I think they're all too expensive." ARS Pharmaceuticals: "I like their a great flier. Someone needs that technology, someone's going to pay for it." NuScale Power: "...If it does an offering here, that's when I'd buy. I'd wait for the stock offering after what happened with Oklo tonight." Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest
Yahoo
16-05-2025
- Business
- Yahoo
BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 14.8% year on year to $745.1 million. The company expects the full year's revenue to be around $3.15 billion, close to analysts' estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts' consensus estimates. Is now the time to buy BMRN? Find out in our full research report (it's free). Revenue: $745.1 million vs analyst estimates of $738.1 million (14.8% year-on-year growth, 1% beat) Adjusted EPS: $1.13 vs analyst estimates of $0.95 (18.6% beat) Adjusted Operating Income: $265.7 million vs analyst estimates of $158.5 million (35.7% margin, 67.7% beat) The company reconfirmed its revenue guidance for the full year of $3.15 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $4.30 at the midpoint Operating Margin: 30%, up from 13.6% in the same quarter last year Free Cash Flow Margin: 21.2%, up from 3.2% in the same quarter last year Market Capitalization: $11.17 billion BioMarin's first quarter results were shaped by continued growth in its VOXZOGO therapy for achondroplasia and solid contributions from its Enzyme Therapies portfolio. Management highlighted that VOXZOGO achieved strong year-over-year revenue gains, supported by expanded patient access across 49 countries and increased adoption in younger age groups following recent guideline updates. Enzyme Therapies also delivered, with PALYNZIQ and ALDURAZYME posting notable growth, and operating expenses reflecting benefits from recent cost transformation initiatives. Looking forward, leadership reaffirmed full-year guidance and emphasized plans for increased investment in research and development, particularly for ongoing VOXZOGO indications and pipeline programs like BMN 351 and BMN 333. CEO Alexander Hardy stressed BioMarin's resilience to sector headwinds, citing the company's global revenue base and limited Medicare exposure. BioMarin anticipates higher revenues in the second half of the year, with new product launches and clinical milestones expected to drive future growth. Management attributed first quarter outperformance to robust commercial execution and strategic focus on expanding access for key therapies. The following major themes emerged from the call: VOXZOGO international expansion: BioMarin's VOXZOGO therapy for achondroplasia continued to grow, now available in 49 countries. Management noted that international markets contributed about 75% of VOXZOGO revenues, with ongoing efforts to open access in over 60 countries by 2027. Adoption in younger patients: New international guidelines recommending early diagnosis and treatment have driven increased uptake among infants and young children in the U.S., following regulatory approval for these age groups at the end of last year. Enzyme Therapies growth: The Enzyme Therapies unit delivered 8% year-over-year growth, with PALYNZIQ and ALDURAZYME showing strong demand. Management highlighted PALYNZIQ's potential for expanded adolescent indications, supported by positive pivotal data and regulatory submissions planned for later this year. Operational efficiency impact: Cost transformation efforts led to lower year-over-year R&D and SG&A expenses in Q1, boosting operating margins. However, spending is expected to rise through the rest of the year as BioMarin invests in new launches and pipeline programs. Minimal tariff exposure: Leadership explained that BioMarin's global manufacturing footprint and small U.S. Medicare patient base limit exposure to potential pharmaceutical tariffs or policy changes, insulating the business from some external risks. BioMarin's outlook for the remainder of the year is anchored in expanding indications for existing therapies, new product pipeline progress, and continued global market penetration. Pipeline advancement: Management expects clinical milestones from late-stage pipeline programs—such as VOXZOGO in hypochondroplasia, PALYNZIQ for adolescents, and initial data from BMN 351 for Duchenne Muscular Dystrophy—to support future growth and potential product launches. Commercial execution in new markets: The company aims to further expand access to VOXZOGO and Enzyme Therapies worldwide, with strategic focus on increasing prescriber awareness and broadening reimbursement pathways, particularly outside the U.S. Operational investment: Planned increases in R&D and SG&A spending are intended to accelerate growth in core franchises and support launches, but management cautioned that this could moderate margins in coming quarters. External risks such as evolving tariff policies remain an area of ongoing monitoring. Philip Nadeau (TD Cowen): Asked if VOXZOGO revenue could decline in Q2 and how future pharmaceutical tariffs might affect financials. Management clarified that order timing dynamics could make Q2 flat or down, and said they are modeling tariff scenarios but have limited current exposure. Tommie Reerink (Goldman Sachs): Inquired about business development timing and the detail of upcoming BMN 333 data. CEO Alexander Hardy reiterated a focus on executing at least one business development transaction this year, and R&D leadership expects topline pharmacokinetic results for BMN 333 later in 2025. Jenny Gonzalez-Armenta (Leerink Partners): Sought details on strategies to expand VOXZOGO adoption. Chief Commercial Officer Cristin Hubbard described targeted awareness campaigns, expanded field teams, and prescriber base expansion, especially among pediatric endocrinologists. Zaki Molvi (Jefferies): Questioned BMN 351's safety profile given preclinical liver signals. Chief R&D Officer Greg Friberg said the candidate was engineered for safety and detailed ongoing clinical monitoring, with full safety and efficacy data to be presented later this year. Jessica Fye (JPMorgan): Asked how BioMarin would address market concerns about VOXZOGO's long-term value beyond 2030. Management emphasized the large and growing dataset on efficacy and safety, broad international footprint, and next-generation candidates like BMN 333. The StockStory team will be watching (1) progress on key clinical milestones, including data releases for VOXZOGO in hypochondroplasia and BMN 351 for Duchenne Muscular Dystrophy, (2) expansion of VOXZOGO access in new geographies and patient age groups, and (3) the outcome of regulatory submissions for PALYNZIQ adolescent indications in the U.S. and Europe. Developments in business development activities and tariff policy changes may also influence future performance. BioMarin Pharmaceutical currently trades at a forward P/E ratio of 13.1×. Should you load up, cash out, or stay put? The answer lies in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
Let's dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth. The 10 therapeutics stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.2%. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 11% since the latest earnings results. Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. AbbVie reported revenues of $13.34 billion, up 8.4% year on year. This print exceeded analysts' expectations by 3.3%. Overall, it was a very strong quarter for the company with a solid beat of analysts' constant currency revenue estimates and a decent beat of analysts' EPS estimates. "AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year," said Robert A. Michael, chief executive officer, AbbVie. The stock is up 2.2% since reporting and currently trades at $184.50. Is now the time to buy AbbVie? Access our full analysis of the earnings results here, it's free. Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children. BioMarin Pharmaceutical reported revenues of $745.1 million, up 14.8% year on year, outperforming analysts' expectations by 1%. The business had a strong quarter with a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations. BioMarin Pharmaceutical scored the highest full-year guidance raise among its peers. The market seems unhappy with the results as the stock is down 5.7% since reporting. It currently trades at $59.20. Is now the time to buy BioMarin Pharmaceutical? Access our full analysis of the earnings results here, it's free. Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases. Moderna reported revenues of $108 million, down 35.3% year on year, falling short of analysts' expectations by 8.4%. It was a softer quarter as it posted full-year revenue guidance missing analysts' expectations. Moderna delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update in the group. As expected, the stock is down 16.1% since the results and currently trades at $23.99. Read our full analysis of Moderna's results here. Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Sarepta Therapeutics reported revenues of $744.9 million, up 80.2% year on year. This number topped analysts' expectations by 7.4%. All in all, it was a satisfactory quarter for the company. Sarepta Therapeutics pulled off the fastest revenue growth among its peers. The stock is down 20.8% since reporting and currently trades at $36.95. Read our full, actionable report on Sarepta Therapeutics here, it's free. Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Myriad Genetics reported revenues of $195.9 million, down 3.1% year on year. This print lagged analysts' expectations by 2.3%. Overall, it was a softer quarter as it also logged full-year revenue guidance missing analysts' expectations. The stock is down 41.1% since reporting and currently trades at $4.27. Read our full, actionable report on Myriad Genetics here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Business
- Yahoo
Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here's what investors should know. Vertex Pharmaceuticals beat analysts' revenue expectations by 4.9% last quarter, reporting revenues of $2.91 billion, up 15.7% year on year. It was a strong quarter for the company, with full-year revenue guidance meeting analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 5.4% year on year to $2.83 billion, slowing from the 13.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.29 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates twice over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year-on-year revenue growth of 14.8%, beating analysts' expectations by 1%, and United Therapeutics reported revenues up 17.2%, topping estimates by 5.6%. BioMarin Pharmaceutical traded down 1.3% following the results while United Therapeutics was also down 2.1%. Read our full analysis of BioMarin Pharmaceutical's results here and United Therapeutics's results here. There has been positive sentiment among investors in the therapeutics segment, with share prices up 4.9% on average over the last month. Vertex Pharmaceuticals is up 5.8% during the same time and is heading into earnings with an average analyst price target of $500.32 (compared to the current share price of $501.90). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
05-05-2025
- Business
- Yahoo
Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after market hours. Here's what to look for. Sarepta Therapeutics beat analysts' revenue expectations by 4.3% last quarter, reporting revenues of $658.4 million, up 65.9% year on year. It was a mixed quarter for the company, with a significant miss of analysts' EPS estimates. Is Sarepta Therapeutics a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Sarepta Therapeutics's revenue to grow 67.7% year on year to $693.5 million, improving from the 63.1% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.65 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Sarepta Therapeutics has missed Wall Street's revenue estimates three times over the last two years. Looking at Sarepta Therapeutics's peers in the therapeutics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year-on-year revenue growth of 14.8%, beating analysts' expectations by 1%, and United Therapeutics reported revenues up 17.2%, topping estimates by 5.6%. BioMarin Pharmaceutical traded down 1.3% following the results while United Therapeutics was also down 2.1%. Read our full analysis of BioMarin Pharmaceutical's results here and United Therapeutics's results here. There has been positive sentiment among investors in the therapeutics segment, with share prices up 4.9% on average over the last month. Sarepta Therapeutics is up 22.3% during the same time and is heading into earnings with an average analyst price target of $147.33 (compared to the current share price of $64.07). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. Sign in to access your portfolio
